IP Strategy Must be Woven into Drug Development Process

A conversation with Henry Hadad, Bristol-Myers Squibb

As senior vice president and deputy general counsel for Bristol-Myers Squibb since 2011, Henry Hadad has helped the company navigate the complex intellectual property issues inherent in the successful discovery, development, and commercialization of new drugs, including diligence performed on acquired or licensed products. He shares his thoughts on some of the most effective practices to manage the process.

Hear more from Hadad at the 2019 Bloomberg Law Leadership Forum on May 30 in New York, where corporate counsel from Fortune 500 businesses and leaders from top law firms will gather to discuss ...